TOP TEN perturbations for 1553584_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553584_at
Selected probe(set): 241381_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553584_at (241381_at) across 6672 perturbations tested by GENEVESTIGATOR:

gestational age study 1 (term) / elective termination placenta (1st trim.) tissue

Relative Expression (log2-ratio):2.5922842
Number of Samples:4 / 4
Experimental gestational age study 1 (term)
Term human placenta samples obtained from scheduled uncomplicated C-sections.
Control elective termination placenta (1st trim.) tissue
First trimester placenta samples (45-59 days) obtained from uncomplicated elective termination.

breast cancer study 8 (primary) / normal breast tissue

Relative Expression (log2-ratio):-2.1617584
Number of Samples:13 / 4
Experimental breast cancer study 8 (primary)
Human primary infiltrating ductal carcinoma sample of a female patient with breast cancer.
Control normal breast tissue
Normal human breast samples of healthy female individuals.

FoxO3 H212R overexpr. study 1 / FoxO3 overexpr. study 1

Relative Expression (log2-ratio):2.1139612
Number of Samples:3 / 3
Experimental FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control FoxO3 overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---

breast cancer study 16 (mix. inv. dc lc) / adjacent breast tissue

Relative Expression (log2-ratio):-2.039198
Number of Samples:4 / 27
Experimental breast cancer study 16 (mix. inv. dc lc)
Primary mixed invasive ductal and lobular carcinoma tissue sample derived from the breasts of female patients after surgery.
Control adjacent breast tissue
Histologically normal breast tissue samples obtained from a clinically unaffected site from patients with primary invasive breast cancer.

atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):1.8469658
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

breast cancer study 8 (metastatic) / normal breast tissue

Relative Expression (log2-ratio):-1.7957544
Number of Samples:2 / 4
Experimental breast cancer study 8 (metastatic)
Human metastatic infiltrating ductal carcinoma sample of the breast derived from lymph nodes of a female patient with breast cancer.
Control normal breast tissue
Normal human breast samples of healthy female individuals.

breast cancer study 16 (inv. dc) / adjacent breast tissue

Relative Expression (log2-ratio):-1.7454405
Number of Samples:22 / 27
Experimental breast cancer study 16 (inv. dc)
Primary invasive ductal carcinoma tissue sample derived from the breasts of female patients after surgery.
Control adjacent breast tissue
Histologically normal breast tissue samples obtained from a clinically unaffected site from patients with primary invasive breast cancer.

breast cancer study 15 (inv. dc) / normal breast tissue

Relative Expression (log2-ratio):-1.5780678
Number of Samples:5 / 5
Experimental breast cancer study 15 (inv. dc)
Primary invasive ductal carcinoma tissue sample derived from the breasts of female patients after surgery.
Control normal breast tissue
Tissue samples of the breast from healthy female individuals after breast reduction surgery.

breast cancer study 16 (inv. lc) / adjacent breast tissue

Relative Expression (log2-ratio):-1.5354509
Number of Samples:5 / 27
Experimental breast cancer study 16 (inv. lc)
Primary invasive lobular carcinoma tissue sample derived from the breasts of female patients after surgery.
Control adjacent breast tissue
Histologically normal breast tissue samples obtained from a clinically unaffected site from patients with primary invasive breast cancer.

endometriosis study 5 (endo. lesion; proliferative MCP) / endometriosis study 5 (eutopic endometrium; proliferative MCP)

Relative Expression (log2-ratio):1.5332403
Number of Samples:8 / 8
Experimental endometriosis study 5 (endo. lesion; proliferative MCP)
Peritoneal endometriosis lesion samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, and the knowledge of the patient’s last menstrual cycle.
Control endometriosis study 5 (eutopic endometrium; proliferative MCP)
Eutopic endometrial tissue samples collected from women with endometriosis in the proliferative menstrual cycle phase (MCP). The endometrial samples were obtained by laparoscopy or laparotomy. Women had complete MCPs including those patients where hormone therapy was stopped at 3 to 6 months before surgery. The MCP was determined according to a combination of measurement of hormone serum levels, gene expression of a cycle-phase specific genes, the knowledge of the patient’s last menstrual cycle, and analysis of specific histological criteria to identify menstrual cycle phases.